دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Cover Image
Janet B. McGill MD, Rajiv Agarwal MD, Stefan D. Anker MD, George L. Bakris MD, Gerasimos Filippatos MD, Bertram Pitt MD, Luis M. Ruilope MD, Andreas L. Birkenfeld MD, Maria L. Caramori MD, Meike Brinker MD, Amer Joseph MBBS, Andrea Lage MD, Robert Lawatscheck MD, Charlie Scott MSc, Peter Rossing MD, on behalf of the FIDELIO-DKD and FIGARO-DKD investigators ,Â
doi : 10.1111/dom.15115
Volume 25, Issue 6
Nonalcoholic fatty liver disease from a primary care perspective
Jeanne M. Clark MD, Donna R. H. Cryer JD, Michelle Morton MSN, Jay H. Shubrook DO,Â
doi : 10.1111/dom.15016
Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes
Biff F. Palmer MD,Â
doi : 10.1111/dom.15030
A cross-sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa (PACT-MEA): Study design and rationale
Subodh Verma MD, Hani Sabbour MD, Naji Alamuddin MD, Fatheya Alawadi MD, Hessa Alkandari MD, Wael Almahmeed MD, Samir H. Assaad-Khalil MD, Jihad Haddad MD, Landman Lombard MBChB, Rayaz A. Malik MBChB, Emel Mashaki Ceyhan PharmD, Preethy Prasad PhD, Gamze Tombak MD, Sam Salek PhD,Â
doi : 10.1111/dom.15011
To investigate the epidemiology and clinical management of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (eASCVD) or high/very high ASCVD risk, defined by the 2021 European Society of Cardiology Guidelines, in seven countries in the Middle East and Africa (PACT-MEA; NCT05317845), and to assess physicians' attitudes and the basis for their decision-making in the management of these patients.
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial
Julio Rosenstock MD, Ahmed A. Kolkailah MD, Darren K. McGuire MD, Mark A. Espeland PhD, Michaela Mattheus MSc, Egon Pfarr MSc, Søren S. Lund MD, Nikolaus Marx MD, on behalf of the CAROLINA Investigators ,Â
doi : 10.1111/dom.14991
The CAROLINA trial established non-inferiority of linagliptin versus glimepiride for major adverse cardiovascular events in patients with relatively early type 2 diabetes at increased cardiovascular risk. In pre-specified and post-hoc analyses, we investigated treatment effects on total hypoglycaemic burden in CAROLINA.
Long-term impact of weight loss for people with overweight but not obesity, and with type 2 diabetes: 10-year outcomes of a randomized trial of gastric band surgery
Qi Yang Damien Qi MBBS, Julie Playfair BHSc, Wendy A. Brown MBBS, Paul Burton MBBS, Paul E. O'Brien MBBS, John M. Wentworth MBBS,Â
doi : 10.1111/dom.14992
Randomized trials reporting 5-year outcomes have shown bariatric surgery  to induce diabetes remission and improve cardiovascular risk. However, the longer-term effects of surgery are uncertain, with only one randomized trial reporting 10-year diabetes outcomes in people with obesity. We aimed to compare 10-year diabetes outcomes of people who are overweight but not obese, randomly assigned to receive either multidisciplinary diabetes care, or multidisciplinary diabetes care combined with gastric band (GB) surgery.
Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Jennifer B. Green MD, Peter Merrill PhD, Yuliya Lokhnygina PhD, Robert J. Mentz MD, Joakim Alfredsson PhD, Rury R. Holman MBChB, on behalf of the EXSCEL Study Group ,Â
doi : 10.1111/dom.14993
To examine sex differences in the characteristics and outcomes in participants with type 2 diabetes (T2D), with or without cardiovascular disease (CVD), randomized to once-weekly exenatide (EQW) or placebo in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study
Grit Andersen MD, Gursharan Singh PhD, Sundara Moorthi Nainar Murugesan PhD, Rajesh Gogineni MPharm, Nirant Sharma MSc, Jayanti Panda MPharm, Ashwani Marwah MSc, Subramanian Loganathan MD, Sandeep N. Athalye MD,Â
doi : 10.1111/dom.14994
To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar Insulin N (Biocon's Insulin-N; Biocon Biologics Ltd., Bangalore, India) and US-licensed Humulin® N (Humulin-N; Eli Lilly and Company, Indianapolis, IN, USA) in healthy subjects.
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials
João Pedro Ferreira MD, Francisca Saraiva PhD, Abhinav Sharma MD, Francisco Vasques-Nóvoa MD, António Angélico-Gonçalves MD, Ana Rita Leite MD, Marta Borges-Canha MD, Davide Carvalho MD, Milton Packer MD, Faiez Zannad MD, Adelino Leite-Moreira MD, João Sérgio Neves MD,Â
doi : 10.1111/dom.14997
Glucagon-like peptide 1 receptor agonists (GLP1-RA) reduce atherosclerotic events in patients with type 2 diabetes (T2D) and a high cardiovascular risk. The effect of GLP1-RA to reduce heart failure (HF) has been inconsistent across T2D trials, and individual trials were underpowered to assess the effect of GLP1-RA according to HF history. In this meta-analysis we aim to assess the effect of GLP1-RA in patients with and without HF history in stable ambulatory patients with T2D.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)
Yuka Takahashi MD, Hiroshi Nomoto MD, Hiroki Yokoyama MD, Yoshinari Takano MD, So Nagai MD, Atsushi Tsuzuki MD, Kyu Yong Cho MD, Aika Miya MD, Hiraku Kameda MD, Jun Takeuchi MD, Shinji Taneda MD, Yoshio Kurihara MD, Tatsuya Atsumi MD, Akinobu Nakamura MD, Hideaki Miyoshi MD, on behalf of SWITCH-SEMA 1 study group ,
doi : 10.1111/dom.14998
To investigate the effects of switching from liraglutide or dulaglutide to once-weekly semaglutide on glycaemic control and treatment satisfaction in patients with type 2 diabetes.
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline
Janet B. McGill MD, Rajiv Agarwal MD, Stefan D. Anker MD, George L. Bakris MD, Gerasimos Filippatos MD, Bertram Pitt MD, Luis M. Ruilope MD, Andreas L. Birkenfeld MD, Maria L. Caramori MD, Meike Brinker MD, Amer Joseph MBBS, Andrea Lage MD, Robert Lawatscheck MD, Charlie Scott MSc, Peter Rossing MD, on behalf of the FIDELIO-DKD and FIGARO-DKD investigators ,
doi : 10.1111/dom.14999
To evaluate the effect of finerenone by baseline HbA1c, HbA1c variability, diabetes duration and baseline insulin use on cardiorenal outcomes and diabetes progression.
Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study
Nehal Islam MSc, Pauline Reynier MSc, Antonios Douros MD, Oriana H. Y. Yu MD, Kristian B. Filion PhD,Â
doi : 10.1111/dom.15000
To determine whether the use of sulphonylurea monotherapy, compared with metformin monotherapy, is associated with an increased risk of ventricular arrhythmia (VA) among patients initiating pharmacotherapy for type 2 diabetes.
Glucose-dependent insulinotropic polypeptide counteracts diet-induced obesity along with reduced feeding, elevated plasma leptin and activation of leptin-responsive and proopiomelanocortin neurons in the arcuate nucleus
Wanxin Han PhD, Lei Wang PhD, Kento Ohbayashi PhD, Masakazu Takeuchi PhD, Libbey O'Farrell PhD, Tamer Coskun MD, Yermek Rakhat MD, Daisuke Yabe MD, Yusaku Iwasaki PhD, Yutaka Seino MD, Toshihiko Yada PhD,Â
doi : 10.1111/dom.15001
To clarify the effects of glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (GIPRAs) on feeding and body weight.
Effects of somatostatin receptor type 2 antagonism during insulin-induced hypoglycaemia in male rats with prediabetes
Emily G. Hoffman BSc, Ninoschka C. D'Souza MSc, Julian Aiken PhD, Sara Atherley BSc, Richard Liggins PhD, Michael C. Riddell PhD,
doi : 10.1111/dom.15002
To examine if glucagon counterregulatory defects exist in a rat model of prediabetes (pre-T2D) and to assess if a selective somatostatin receptor 2 antagonist (SSTR2a), ZT-01, enhances the glucagon response to insulin-induced hypoglycaemia.
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia
Julie Maria Bøggild Brøsen MD, Rikke Mette Agesen PhD, Peter Lommer Kristensen PhD, Amra Ciric Alibegovic PhD, Henrik Ullits Andersen DMSc, Henning Beck-Nielsen DMSc, Peter Gustenhoff MD, Troels Krarup Hansen DMSc, Christoffer Hedetoft PhD, Tonny Jensen DMSc, Charlotte Røn Stolberg PhD, Claus Bogh Juhl DMSc, Susanne Søgaard Lerche PhD, Kirsten Nørgaard DMSc, Hans-Henrik Parving DMSc, Lise Tarnow DMSc, Birger Thorsteinsson DMSc, Ulrik Pedersen-Bjergaard DMSc,
doi : 10.1111/dom.15003
To compare nocturnal glucose profiles according to hourly plasma glucose measurements during treatment with insulin degludec and insulin glargine U100 in a cohort of people with type 1 diabetes prone to nocturnal severe hypoglycaemia.
Sustained heart rate-corrected QT prolongation during recovery from hypoglycaemia in people with type 1 diabetes, independently of recovery to hyperglycaemia or euglycaemia
Christine R. Andreasen MD, Andreas Andersen PhD, Per G. Hagelqvist MD, Kaisar Maytham BSc, Julius V. Lauritsen BSc, Susanne Engberg PhD, Jens Faber MD, Ulrik Pedersen-Bjergaard MD, Filip K. Knop MD, Tina Vilsbøll MD,Â
doi : 10.1111/dom.15005
To investigate changes in cardiac repolarization abnormalities (heart rate-corrected QT [QTc] [primary endpoint], T-wave abnormalities) and heart-rate variability measures in people with type 1 diabetes during insulin-induced hypoglycaemia followed by recovery hyperglycaemia versus euglycaemia.
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study
Shigenori Hiruma MD, Fumika Shigiyama MD, Naoki Kumashiro MD,Â
doi : 10.1111/dom.15006
To compare the effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 inhibitors on ectopic fat accumulation and tissue-specific insulin sensitivity.
Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis
Shashank R. Joshi MD, Gursharan Singh PhD, Ashwani Marwah MSc, Shivani Mittra PhD, Viraj R. Suvarna MD, Sandeep N. Athalye MD,Â
doi : 10.1111/dom.15007
To compare the clinical efficacy and safety of glargine-U100 (Lantus/Gla-100) with glargine-U300 (Toujeo/Gla-300) in adult patients with type 2 diabetes (T2D) and type 1 diabetes (T1D).
One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany
Pierre-Yves Benhamou MD, Alice Adenis MSc, Hocine Lebbad MSc, Yousra Tourki MSc, Maria-Belen Heredia MSc, Bernhard Gehr MD, Sylvia Franc MD, Guillaume Charpentier MD,Â
doi : 10.1111/dom.15008
The Diabeloop Generation 1 (DBLG1) system is an interoperable hybrid closed-loop solution that was commercialized in Germany in March 2021. We report the longitudinal glycaemic outcomes among the first 3706 users in a real-world setting.
Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis
Bao-Ngoc Nguyen PharmD, Le Nguyen PharmD, Shweta Mital PhD, Shawn Bugden PharmD, Hai V. Nguyen PhD,Â
doi : 10.1111/dom.15009
To compare the relative efficacy of sodium-glucose co-transporter 2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs) and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in improving the cardiovascular and renal outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Prevalence of sleep apnoea in patients with type 1 diabetes and its association with comorbidities and diabetic complications: A French nationwide prospective study
Jean-Louis Pépin MD, Sébastien Bailly PhD, Joelle B. Texereau MD, Emmanuel Sonnet MD, Sylvie Picard MD, Bruno Vergès MD, Christine Coffin Boutreux MD, Gwenaelle Arnault Ouary MD, Laurence Kessler MD, Bruno Guerci MD, Brigitte Anton Kuchly MD, Salha Fendri Gaied MD, Alain Cuperlier MD, Christel Voinot MD, Christèle Derrien MD, Séverine Dubois MD, Florent Lavergne MSc, Anne Laure Borel MD, Renaud Tamisier MD, Pierre-Yves Benhamou MD,Â
doi : 10.1111/dom.15015
To investigate sleep apnoea prevalence, factors influencing severity, and associations between sleep apnoea severity and micro-/macrovascular complications in a large population of patients with type 1 diabetes.
Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility
Henriette H. Nerild MD, Andreas Brønden MD, Ida M. Gether MD, Pernille H. Hellmann MD, Mille Baekdal MD, Matthew P. Gillum PhD, Jens S. Svenningsen, Bolette Hartmann PhD, Naveen Rathor MD, Hanna Angelene Kudiyanur Muniraju MSc, Jens F. Rehfeld MD, Jens J. Holst MD, Tina Vilsbøll MD, David P. Sonne MD, Filip K. Knop MD,Â
doi : 10.1111/dom.15017
Liraglutide treatment is associated with gallbladder-related disorders and has been shown to delay postprandial gallbladder refilling. The gut hormones cholecystokinin (CCK), fibroblast growth factor 19 (FGF19) and glucagon-like peptide 2 (GLP-2), are known to regulate gallbladder motility and may be implicated in gallbladder-related disorders associated with liraglutide treatment.
The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme
SokCin Tye PhD, Megumi Oshima PhD, Clare Arnott PhD, Brendon L. Neuen PhD, Robert A. Fletcher PhD, Bruce Neal PhD, Hiddo J. L. Heerspink PhD,Â
doi : 10.1111/dom.15018
To investigate the extent to which improvements in multiple cardiovascular risk markers are associated with a lower risk of cardiovascular and kidney outcomes in patients with type 2 diabetes and high cardiovascular risk participating in the CANVAS programme.
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease
David Z. I. Cherney MD, Ele Ferrannini MD, Guillermo E. Umpierrez MD, Anne L. Peters MD, Julio Rosenstock MD, David R. Powell MD, Michael J. Davies PhD, Phillip Banks MS, Rajiv Agarwal MD,Â
doi : 10.1111/dom.15019
To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2, in adults with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD3).
Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study
Raffaele Napoli MD, Cesare Berra MD, Andrei-Mircea Catarig MD, Chiara Di Loreto PhD, Emily Donatiello MSc.Pharm, Tina Landsvig Berentzen PhD, Dario Pitocco MD, Francesco Giorgino MD,Â
doi : 10.1111/dom.15020
SURE Italy, a multicentre, prospective, open-label, observational, real-world study, investigated once-weekly semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice.
Machine learning for non-invasive sensing of hypoglycaemia while driving in people with diabetes
Vera Lehmann MD, Thomas Zueger MD, Martin Maritsch PhD, Mathias Kraus PhD, Caroline Albrecht BSc, Caterina Bérubé MSc, Stefan Feuerriegel PhD, Felix Wortmann PhD, Tobias Kowatsch PhD, Naïma Styger BSc, Sophie Lagger MSc, Markus Laimer MD, Elgar Fleisch PhD, Christoph Stettler MD,Â
doi : 10.1111/dom.15021
To develop and evaluate the concept of a non-invasive machine learning (ML) approach for detecting hypoglycaemia based exclusively on combined driving (CAN) and eye tracking (ET) data.
Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen
Jieling Chen PhD, Ludi Fan PhD, Keisha Maughn MPH, Gabriel G. Rey MS, Yi Liu PhD, David R. Nelson MS, Robert C. Hood MD,Â
doi : 10.1111/dom.15022
To identify patient clusters with poor glucose control among type 2 diabetes mellitus (T2DM) patients with obesity who are receiving basal-bolus insulin and to identify the potential therapeutic inertia factors associated with poor control.
Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system
Bruno Grassi MD, Ana Maria Gómez MD, Luis Eduardo Calliari MD, Denise Franco MD, Marcela Raggio MD, Francisca Riera MD, Matias Castro MPhil, Jennifer McVean MD, Tim van den Heuvel PhD, Arcelia Arrieta MSc, Javier Castañeda MSc, Ohad Cohen MD,Â
doi : 10.1111/dom.15023
We studied real-world performance of MiniMed (MM) 780G system users from Argentina, Brazil, Colombia and Chile (geographical analysis), and the effect of each technology iteration of the MM system on glycaemic control (technology iteration analysis).
Trends and cyclic variation in the incidence of childhood type 1 diabetes in two Italian regions over 33 years and during the COVID-19 pandemic
Rosaria Gesuita PhD, Ivana Rabbone MD, Vittorio Marconi MD, Luisa De Sanctis MD, Monica Marino RD, Valentina Tiberi MD, Antonio Iannilli MD, Davide Tinti MD, Lucia Favella PM, Carlo Giorda MD, Flavia Carle PhD, Valentino Cherubini MD,Â
doi : 10.1111/dom.15024
There is conflicting evidence about the impact of the COVID-19 pandemic on the incidence of type 1 diabetes. Here, we analysed long-term trends in the incidence of type 1 diabetes in Italian children and adolescents from 1989 to 2019 and compared the incidence observed during the COVID-19 pandemic with that estimated from long-term data.
Use of the FreeStyle Libre system and diabetes treatment progression in T2DM: Results from a retrospective cohort study using a Canadian private payer claims database
Stewart B. Harris MD, Fleur Levrat-Guillen PharmD,Â
doi : 10.1111/dom.15025
Up to one-third of Canadians are estimated to be living with prediabetes or diabetes. A retrospective study using Canadian private drug claims data was conducted to investigate whether flash glucose monitoring using the FreeStyle Libre system (FSL) among people with type 2 diabetes mellitus (T2DM) in Canada can be associated with changes in treatment intensification when compared with blood glucose monitoring (BGM) alone.
Association between residual islet beta-cell function and achieving the target of time in range in inpatients with type 2 diabetes undergoing antidiabetic treatment: An observation study
Zhang Xia PhD, Wenjun You MM, Yuhao Li MM, Feng Li MM, Shuai Hao MM, Yihan Sun MM, Na Li MM, Lu Lin PhD, Jingtao Dou PhD, Xin Su PhD, Qi Zhai MM, Yingting Zuo PhD, Yibo Zhang MM, Herbert Y. Gaisano MD, Deqiang Zheng PhD, Yan He PhD, Jiajia Jiang PhD,Â
doi : 10.1111/dom.15026
To assess whether the beta-cell function of inpatients undergoing antidiabetic treatment influences achieving time in range (TIR) and time above range (TAR) targets.
iGlarLixi (insulin glargine 100Â U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data
Cristian Guja MD, János Tibor Kis MD, Martin HaluzÃk MD, Mireille Bonnemaire MD, Gregory Bigot MSc, Mathilde Tournay MSc, Nick Freemantle PhD, Jochen Seufert MD,Â
doi : 10.1111/dom.15027
To evaluate the effectiveness and safety in routine clinical practice of insulin glargine/lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) according to age.
Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single-blind placebo-controlled study
Preeshila Behary PhD, Haya Alessimii PhD, Alexander D. Miras PhD, George Tharakan PhD, Kleopatra Alexiadou PhD, Madhawi M. Aldhwayan PhD, Sanjay Purkayastha MD, Krishna Moorthy MD, Ahmed R. Ahmed PhD, Stephen R. Bloom FRS, Tricia M. Tan PhD,Â
doi : 10.1111/dom.15028
To investigate whether the elevation in postprandial concentrations of the gut hormones glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM) and peptide YY (PYY) accounts for the beneficial changes in food preferences, sweet taste function and eating behaviour after Roux-en-Y gastric bypass (RYGB).
Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes
Tina Vilsbøll MD, Caroline Ø. Lindahl MSc, Nick F. Nielsen PhD, Christian K. Tikkanen MSc,Â
doi : 10.1111/dom.15031
To investigate the impact of treatment with once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), for up to 2 years in people with type 2 diabetes (T2D) managed in routine clinical practice.
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study
Suzanne V. Arnold MD, James A. de Lemos MD, Luke Zheng BS, Robert S. Rosenson MD, Christie M. Ballantyne MD, Shushama Alam PharmD, Deepak L. Bhatt MD, Christopher P. Cannon MD, Mikhail Kosiborod MD, on behalf of the GOULD Investigators ,Â
doi : 10.1111/dom.15032
To examine improvement in the use of optimal medical therapy (OMT) for secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) and diabetes.
Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study
Annemarie B. van der Aart-van der Beek PharmD, Ellen Apperloo MD, Niels Jongs PhD, Dennis B. Rouw MD, C. David Sjöström MD, Iris Friedli PhD, Lars Johansson PhD, Daniël H. van Raalte MD, Klaas Hoogenberg MD, Hiddo J. L. Heerspink PhD,Â
doi : 10.1111/dom.15033
To evaluate the albuminuria-lowering effect of dapagliflozin, exenatide, and the combination of dapagliflozin and exenatide in patients with type 2 diabetes and microalbuminuria or macroalbuminuria.
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin
Byungwook Kim MD, Dha Woon Im MD, Heejae Won PharmD, Jung Sunwoo MD, Seung Seok Han MD, Hajeong Lee MD, Dong Ki Kim MD, Kook-Hwan Oh MD, Kwon Wook Joo MD, Yon Su Kim MD, Joo-Youn Cho PharmD, SeungHwan Lee MD, Jaeseong Oh MD, In-Jin Jang MD, Yong Chul Kim MD,Â
doi : 10.1111/dom.15034
To investigate the possible effect of haemodialysis (HD) on the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of evogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Safety and efficacy of sodium-glucose co-transporter-2 inhibitors in patients with kidney transplantation and diabetes mellitus
Aparna Yeggalam MD, Jessica Ann Liebich BS, Kevin Yu BA, Ekta Shrestha MD, Srikanth Nadella MD, Vaishaliben Ahir MD, Jennifer Newman BSN, Krista L. Lentine MD, Yasar Caliskan MD, Fadee Abu Al Rub MD, Sandeep Dhindsa MD, Stewart G. Albert MD,Â
doi : 10.1111/dom.15035
